
Christilla Bachelot-Loza

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5394043/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Role of oculocerebrorenal syndrome of Lowe (OCRL) protein in megakaryocyte maturation, platelet production and functions: a study in patients with Lowe syndrome. British Journal of Haematology, 2021, 192, 909-921.	1.2	6
2	Role of Membrane Lipid Rafts in MRP4 (ABCC4) Dependent Regulation of the cAMP Pathway in Blood Platelets. Thrombosis and Haemostasis, 2021, 121, 1628-1636.	1.8	3
3	Endoglin Is an Endothelial Housekeeper against Inflammation: Insight in ECFC-Related Permeability through LIMK/Cofilin Pathway. International Journal of Molecular Sciences, 2021, 22, 8837.	1.8	3
4	Assessing bleeding risk in 18 children with Osteogenesis imperfecta. British Journal of Haematology, 2021, 192, 785-788.	1.2	1
5	Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases. International Journal of Molecular Sciences, 2021, 22, 13079.	1.8	20
6	Epinephrine restores platelet functions inhibited by ticagrelor: A mechanistic approach. European Journal of Pharmacology, 2020, 866, 172798.	1.7	10
7	Platelet Functions During Extracorporeal Membrane Oxygenation. Platelet–Leukocyte Aggregates Analyzed by Flow Cytometry as a Promising Tool to Monitor Platelet Activation. Journal of Clinical Medicine, 2020, 9, 2361.	1.0	12
8	Comparative In Vitro Study of Various α2-Adrenoreceptor Agonist Drugs for Ticagrelor Reversal. Journal of Clinical Medicine, 2020, 9, 809.	1.0	1
9	P2Y12 Inhibition beyond Thrombosis: Effects on Inflammation. International Journal of Molecular Sciences, 2020, 21, 1391.	1.8	65
10	Effect of rivaroxaban and dabigatran on platelet functions: in vitro study. Thrombosis Research, 2019, 183, 159-162.	0.8	9
11	Evidence that MRP4 is Only Partly Involved in S1P Secretion during Platelet Activation. Thrombosis and Haemostasis, 2018, 118, 1116-1118.	1.8	6
12	Synergistic effect of peptide inhibitors derived from the extracellular and intracellular domain of αIIb subunit of integrin αIIbβ3 on platelet activation and aggregation. Platelets, 2018, 29, 34-40.	1.1	4
13	Human endoglin as a potential new partner involved in platelet–endothelium interactions. Cellular and Molecular Life Sciences, 2018, 75, 1269-1284.	2.4	30
14	Evolution of platelet functions in cirrhotic patients undergoing liver transplantation: A prospective exploration over a month. PLoS ONE, 2018, 13, e0200364.	1.1	7
15	Ticagrelor reversal:in vitroassessment of four haemostatic agents. Journal of Clinical Pathology, 2017, 70, 733-739.	1.0	14
16	Platelet-mapping assay for monitoring antiplatelet therapy during mechanical circulatory support in children: A retrospective observational study. Research and Practice in Thrombosis and Haemostasis, 2017, 1, 120-127.	1.0	7
17	The effectiveness of platelet supplementation for the reversal of ticagrelor-induced inhibition of platelet aggregation. European Journal of Anaesthesiology, 2016, 33, 361-367.	0.7	47
18	MRP4 (ABCC4) as a potential pharmacologic target for cardiovascular disease. Pharmacological Research, 2016, 107, 381-389.	3.1	45

Christilla Bachelot-Loza

#	Article	IF	CITATIONS
19	Impaired platelet activation and cAMP homeostasis in MRP4-deficient mice. Blood, 2015, 126, 1823-1830.	0.6	51
20	Inhibition of αIIbβ3 Ligand Binding by an αIIb Peptide that Clasps the Hybrid Domain to the βI Domain of β3. PLoS ONE, 2015, 10, e0134952.	1.1	1
21	Primary haemostasis disorders in Lowe syndrome patients. Sang Thrombose Vaisseaux, 2014, 26, 174-180.	0.1	0
22	Impact of Aspirin and Clopidogrel Interruption on Platelet Function in Patients Undergoing Major Vascular Surgery. PLoS ONE, 2014, 9, e104491.	1.1	18
23	Biphasic myosin II light chain activation during clot retraction. Thrombosis and Haemostasis, 2013, 110, 1215-1222.	1.8	11
24	short report: Bleeding disorders in Lowe syndrome patients: evidence for a link between <i>OCRL</i> mutations and primary haemostasis disorders. British Journal of Haematology, 2010, 150, 685-688.	1.2	19
25	Platelet dysfunction after normothermic cardiopulmonary bypass in children: Effect of high-dose aprotinin. Thrombosis and Haemostasis, 2007, 98, 385-391.	1.8	8
26	Platelet dysfunction after normothermic cardiopulmonary bypass in children: effect of high-dose aprotinin. Thrombosis and Haemostasis, 2007, 98, 385-91.	1.8	4
27	Adenosine Diphosphate–Induced Platelet Aggregation Is Associated WithP2Y12Gene Sequence Variations in Healthy Subjects. Circulation, 2003, 108, 989-995.	1.6	402